Endomyocardial Biopsies in the Diagnostic Workup of Immune Checkpoint Inhibitor Associated Myocarditis.

Keila C Ostos-Mendoza, Hadi Al Etri, Carlos Manuel Martínez Cerda, Cezar Iliescu, Nicolas L Palaskas

Abstract readReview

In one paragraph

Review in Current heart failure reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Keila C Ostos-MendozaDepartment of Cardiology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1451, Houston, TX, 77030, USA.

Hadi Al EtriGilbert And Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, Lebanon.

Carlos Manuel Martínez CerdaDepartment of Cardiology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1451, Houston, TX, 77030, USA.

Cezar IliescuDepartment of Cardiology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1451, Houston, TX, 77030, USA.

Nicolas L PalaskasDepartment of Cardiology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1451, Houston, TX, 77030, USA. NLPalaskas@mdanderson.org.ORCID http://orcid.org/0000-0001-7565-1797

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo identify the role of endomyocardial biopsy in the diagnosis, prognostication, and future understanding of mechanisms for immune checkpoint inhibitor myocarditis. RECENT

findingsThe use of endomyocardial biopsy in immune checkpoint inhibitor myocarditis has led to recognizing a spectrum of disease that correlates with mild symptoms to more fulminant presentations. The primary infiltrate observed is CD8+ T cells but more studies are suggesting that the presence of CD68+ macrophages may portend worse prognosis. Currently, endomyocardial biopsy still has a role in diagnosing immune checkpoint inhibitor myocarditis especially when there is uncertainty from non-invasive diagnostic tools. Emerging evidence suggests endomyocardial biopsy can help with prognosis determination and potentially even guide future cancer therapy. Future research into understanding mechanisms of immune checkpoint inhibitor myocarditis will require endomyocardial biopsy for tissue acquisition.

Indexed as

Immune Checkpoint InhibitorsMyocarditisMyocardiumBiopsyHumansPrognosisImmune Checkpoint InhibitorsEndomyocardial biopsyImmune checkpoint inhibitorsMyocarditis

Identifiers

PMID42599618

DOI10.1007/s11897-026-00775-8

PMCPMC13476337

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.